Please assess the completion status of the following clinical trial:

Trial Title: Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed type 2 diabetic patients.~2. Hospitalization due to hyperglycemia hyperosmolality syndrome.~3. Those who age between 30 and 80 years old and can inject insulin by themselves.~Exclusion Criteria:~1. Pregnant women.~2. Impaired liver function (ALT \> 120 U/L)~3. Impaired renal function (Serum creatinine \>3.0 mg/dL)~4. Recently suffered from MI or CVA.~5. Patients are acute intercurrent illness.~6. 2-hour C-peptide level \< 1.8 ng/mL.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Insulin (Type: EXPERIMENTAL): Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard. Two third of daily dose was administered before breakfast and the other was administered at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre-breakfast dose was titrated base on pre-supper blood glucose.
- OAD (Type: ACTIVE_COMPARATOR): Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was \<70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose \>160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.

Based on this trial design, predict the completion outcome and termination type (if applicable).